Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases
This study provides Class II evidence that plasma NfL/p-tau217 discriminates patients with CJD from those with AD and Diagnosing AD with a single abnormal p-tau plasma biomarker risks misdiagnosing prion diseases as AD.